{"id":385626,"date":"2020-11-19T16:22:20","date_gmt":"2020-11-19T21:22:20","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=385626"},"modified":"2020-11-19T16:22:20","modified_gmt":"2020-11-19T21:22:20","slug":"mesoblast-corporate-update-and-financial-results-webcast","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/","title":{"rendered":"Mesoblast Corporate Update and Financial Results Webcast"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">NEW YORK, Nov.  19, 2020  (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021).<\/p>\n<p align=\"start\">\n        <strong>Conference Call Details\u00a0<\/strong><br \/>\n        <br \/> The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via https:\/\/webcast.boardroom.media\/mesoblast-limited\/20201119\/NaN5fb59c68f297810019932232<\/p>\n<p align=\"start\">The archived webcast will be available on the Investor page of the Company\u2019s website: <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w_okTP5M_qCRw9iyWG8Vu2nlSPq8hkrDz60JgmX74tg4U9l4_HElKYR01xey7Gc1RRgiAepfaCfj7133b61x8g==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.mesoblast.com<\/u><\/a><\/p>\n<p align=\"start\">\n        <strong>About Mesoblast<\/strong><br \/>\n        <br \/> Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of commercial products and late-stage product candidates. Mesoblast has a strong and extensive global intellectual property (IP) portfolio with protection extending through to at least 2040 in all major markets. The Company\u2019s proprietary manufacturing processes yield industrial-scale, cryopreserved, off-the-shelf, cellular medicines. These cell therapies, with defined pharmaceutical release criteria, are planned to be readily available to patients worldwide.\u00a0<\/p>\n<p align=\"start\">Remestemcel-L is being developed for inflammatory diseases in children and adults including steroid-refractory acute graft versus host disease and moderate to severe acute respiratory distress syndrome. Mesoblast is completing Phase 3 trials for its product candidates for advanced heart failure and chronic low back pain. Two products have been commercialized in Japan and Europe by Mesoblast\u2019s licensees, and the Company has established commercial partnerships in Europe and China for certain Phase 3 assets.\u00a0<\/p>\n<p align=\"start\">Mesoblast has locations in Australia, the United States and Singapore and is listed on the Australian Securities Exchange (MSB) and on the Nasdaq (MESO). For more information, please see <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=w_okTP5M_qCRw9iyWG8Vu7kRZKVi5b7LLtGFwtkxgZTesS01_M86wd2Q-XT-jySzJtEC-cm5JHyuhqB37LwDFw==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>www.mesoblast.com<\/u><\/a>, LinkedIn: Mesoblast Limited and Twitter: @Mesoblast<\/p>\n<p align=\"start\">Release authorized by the Chief Executive.<\/p>\n<p align=\"start\">\n        <em>For further information, please contact:<\/em>\n      <\/p>\n<table style=\"border-collapse: collapse;width:100%;border-collapse:collapse\">\n<tr>\n<td style=\"max-width:45%;width:45%;min-width:45%;text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong><br \/>\n              <em>Media<\/em><br \/>\n            <\/strong><br \/>\n            <br \/> Julie Meldrum <br \/> T: +61 3 9639 6036 <br \/> E:<a href=\"mailto:julie.meldrum@mesoblast.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>julie.meldrum@mesoblast.com<\/u><\/a><\/td>\n<td style=\"max-width:55%;width:55%;min-width:55%;text-align: left;vertical-align: middle;vertical-align: bottom\">Kristen Bothwell <br \/> T: +1 917 613 5434 <br \/> E:<a href=\"mailto:kbothwell@rubenstein.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>kbothwell@rubenstein.com<\/u><\/a><\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\u00a0<\/td>\n<\/tr>\n<tr>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">\n            <strong><br \/>\n              <em>Investors<\/em><br \/>\n            <\/strong><br \/>\n            <br \/> Schond Greenway <br \/> T: +212 880 2060 <br \/> E:\u00a0<a href=\"mailto:schond.greenway@mesoblast.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>schond.greenway@mesoblast.com<\/u><\/a><\/td>\n<td style=\"text-align: left;vertical-align: middle;vertical-align: bottom\">Paul Hughes\u00a0\u00a0\u00a0 <br \/> T: +61 3 9639 6036 <br \/> E:\u00a0<a href=\"mailto:paul.hughes@mesoblast.com\" rel=\"nofollow noopener noreferrer\" target=\"_blank\"><u>paul.hughes@mesoblast.com<\/u><\/a>\u00a0<\/td>\n<\/tr>\n<\/table>\n<p \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/09d227a2-f11a-4515-aafa-2d9aaeac01ad\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021). Conference Call Details\u00a0 The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via https:\/\/webcast.boardroom.media\/mesoblast-limited\/20201119\/NaN5fb59c68f297810019932232 The archived webcast will be available on the Investor page of the Company\u2019s website: www.mesoblast.com About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Mesoblast Corporate Update and Financial Results Webcast&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-385626","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Mesoblast Corporate Update and Financial Results Webcast - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Mesoblast Corporate Update and Financial Results Webcast - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021). Conference Call Details\u00a0 The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via https:\/\/webcast.boardroom.media\/mesoblast-limited\/20201119\/NaN5fb59c68f297810019932232 The archived webcast will be available on the Investor page of the Company\u2019s website: www.mesoblast.com About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of &hellip; Continue reading &quot;Mesoblast Corporate Update and Financial Results Webcast&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2020-11-19T21:22:20+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Mesoblast Corporate Update and Financial Results Webcast\",\"datePublished\":\"2020-11-19T21:22:20+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/\"},\"wordCount\":346,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/\",\"name\":\"Mesoblast Corporate Update and Financial Results Webcast - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=\",\"datePublished\":\"2020-11-19T21:22:20+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/mesoblast-corporate-update-and-financial-results-webcast\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Mesoblast Corporate Update and Financial Results Webcast\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Mesoblast Corporate Update and Financial Results Webcast - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/","og_locale":"en_US","og_type":"article","og_title":"Mesoblast Corporate Update and Financial Results Webcast - Market Newsdesk","og_description":"NEW YORK, Nov. 19, 2020 (GLOBE NEWSWIRE) &#8212; Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, will host a webcast today to provide a corporate update, and report financial and operational highlights for the first quarter ended September 30, 2020 (FY2021). Conference Call Details\u00a0 The webcast will begin at 9.00am AEDT, Friday, November 20; 5.00pm EST, Thursday, November 19, 2020. It can be accessed via https:\/\/webcast.boardroom.media\/mesoblast-limited\/20201119\/NaN5fb59c68f297810019932232 The archived webcast will be available on the Investor page of the Company\u2019s website: www.mesoblast.com About Mesoblast Mesoblast Limited (Nasdaq:MESO; ASX:MSB) is a world leader in developing allogeneic (off-the-shelf) cellular medicines. The Company has leveraged its proprietary mesenchymal lineage cell therapy technology platform to establish a broad portfolio of &hellip; Continue reading \"Mesoblast Corporate Update and Financial Results Webcast\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/","og_site_name":"Market Newsdesk","article_published_time":"2020-11-19T21:22:20+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Mesoblast Corporate Update and Financial Results Webcast","datePublished":"2020-11-19T21:22:20+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/"},"wordCount":346,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/","name":"Mesoblast Corporate Update and Financial Results Webcast - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=","datePublished":"2020-11-19T21:22:20+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODA4OTU0NiMzODM2NzEzIzIwMTc0MzI="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/mesoblast-corporate-update-and-financial-results-webcast\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Mesoblast Corporate Update and Financial Results Webcast"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385626","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=385626"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/385626\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=385626"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=385626"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=385626"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}